The MARKUS@HOMe editorial team wishes all colleagues a happy New Year's Eve 2025 and a happy, healthy, peaceful, and safe 2026.
We thank all our guests for their academic contributions and look forward to seeing you again in 2026!
youtu.be/hcRC-UQokhs?...
Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis by Drs. Le Gal, Righini et al.
The age-adjusted D-dimer cutoff may safely rule out DVT and was associated with a larger number of patients in whom DVT could be effectively ruled out.
jamanetwork.com/journals/jam...
Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a) by Drs. Nordestgaard, Ridker et al.
Very high Lp(a) levels correlated with increased 30-year risk of CV disease among healthy women.
jamanetwork.com/journals/jam...
Finally, the time has come: Nephrology / Hypertension 2025 II
...simultaneously with our 6000th follower!
Who will be on the winner's podium?
youtu.be/W_1GjTPD29E?...
It's that time again!
Nephrology/Hypertension – Top Studies 2025, Part 1!
youtu.be/n3aBxK013bY?...
@gunnarheine.bsky.social @mariamabutair.bsky.social @kronbichlerlab.bsky.social @marcussaemann.bsky.social @sarahelektra.bsky.social
Short-Term DOAC vs. DAPT for Preventing Device Thrombosis Following LAA-Closure: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al.
www.ahajournals.org/doi/10.1161/...
The use of DOACs after LAAC failed to reduce DRT compared with DAPT, but it was associated with an improved safety profile.
The MARKUS@HOME editorial team wishes all colleagues a peaceful and blessed Christmas 2025.
Thank you for your interest in our webinars. We look forward to seeing you again in 2026!
youtu.be/P64PnU0WyZE?...
In our special Christmas episode, Mr. Reinhard Ernst (Wiesbaden) discusses the importance of access to abstract art in general and to abstract expressionism in painting in particular for people in Germany in 2026
youtu.be/HZPtOtj_058?...
Our top-rated cardiology study of 2025 (Best of cardiology: youtu.be/FAOH0tL2Cy8?...)
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction by Drs. Bavendiek, Bauersachs et al.
www.nejm.org/doi/full/10....
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD)
by Drs. Johansen, Biering-Sørensen et al.
www.thelancet.com/journals/lan...
In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.
Extended DOAC Therapy in Provoked VTE - HI-PRO - Prof. Behnood Bikdeli, Prof. Romain Didier
@bbikdeli.bsky.social
youtu.be/e0Orc_Ps56U?...
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease by Drs. Bartholdy, Biering-Sørensen et al.
www.jacc.org/doi/10.1016/...
In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.
Trends in CVE & Bleeding in Advanced CKD: SRR - Dr. M. Evans, Dr. A.-L. Faucon (Stockholm, Sweden)
youtu.be/S2hbWPWkzcU?...
VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN by Drs. Fakhouri, Nester et al.
www.nejm.org/doi/full/10....
Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.
Tonight: Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier
youtu.be/w8qCX2pRSxQ?...
@bbikdeli.bsky.social
Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis by Drs. van Essen, Tromp et al.
www.jacc.org/doi/10.1016/...
Update AF: DECAF & CABG-AF
Gregory Marcus & Florian Herrmann
youtu.be/48AQF8xaW-8?...
Exercise and Kidney Health: Core Curriculum 2026 by Drs. Becerra, Mansour.
www.ajkd.org/article/S027...
This core curriculum reviews the physiology of exercise on kidney function and provides evidence-based strategies for patient counseling and risk reduction.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes by Drs. Nicholls, D’Alessio et al.
www.nejm.org/doi/full/10....
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide.
It's that time again: Best of Cardiologie 2025
youtu.be/FAOH0tL2Cy8?...
Watch now!
It's Congress-Update time!
Check out our new webinar "Post ESC 2025"!
youtu.be/6C6lJWUHlc8?...
Last days of summer...
Tonight it's all about ADPKD!
KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller
youtu.be/qjnYDsYbx0Q?...
@rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Herrington, Staplin et al.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al.
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK)
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
Our experts explain:
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...